ABSTRACT. Cytological diagnosis is not generally conclusive enough to identify histopathological malignancy in canine mammary tumors (CMTs). To establish cytological examination using fine needle biopsy (FNB) samples, gene expressions of hormonal receptors, human epidermal growth factor receptor 2 (HER2), and transcription regulators (Special AT-rich binding protein 1: SATB1 and Snail) were investigated in both tissue and FNB samples of CMTs. In tissue samples of malignant CMTs, especially invasive ones, low expressions of hormonal receptors and high expressions of SATB1 and Snail were detected. On discriminant analysis of tissue samples, 73.2% of CMTs were correctly classified according to histopathological examinations. In FNB samples of malignant CMTs, low expressions of hormonal receptors were detected. On discriminant analysis of FNB samples, 74.2% of CMTs were correctly classified according to histopathological examination. In conclusion, FNB gene expressions had a utility for diagnosis of CMTs malignancy in some degree. By researching more sensitive genes for malignant CMTs, the gene examination of FNB samples from CMTs will become a useful diagnostic tool that can be performed easily without anesthesia and could predict tumor malignancy and invasion prior to surgical removal.
tors (PR), which normal mammary glands should express, are well-known biomarkers associated with histologic tumor malignancy, lymph node involvement, and distant metastasis [11, 14, 26] . Moreover, in a study of ER and PR expression of 113 CMTs, lower PR expression was significantly associated with shorter survival times after surgical removal [11] . In recent years, human epidermal growth factor receptor 2 (HER2, c-erb-2) has been reported to have an important role in tumor aggressiveness. Its overexpression has been detected in 24-30% of human breast cancers [3, 30, 32] . Anti-HER2 antibody is widely used for HER2-overexpressing breast cancers as an antibody drug therapy. In the recent studies of HER2 expression of CMTs, overexpression of this protein was detected in 17.6-35.4% of malignant mammary tumors, and no or faint expression was seen in most benign mammary tumors [16, 20, 22, 25] . However, survival times and survival rates were better in dogs with HER2-overexpressing malignant mammary tumors than in dogs with tumors normally expressing HER2 [20] .
These biomarkers, which are expected to be useful tools not only to classify CMTs as benign or malignant tumors but also to detect highly malignant, invasive tumors, were mainly evaluated using immunohistochemical (IHC) staining techniques. To identify gene biomarkers in CMTs, quantification of the mRNA levels of many genes, includ-ing hormonal receptors and HER2, have been reported [21, 23, 31, 34] . In these studies, mRNA was extracted from mammary tumor tissue samples, but few reports assessed the gene expressions of biomarkers in FNB samples.
Special AT-rich binding protein 1 (SATB 1) is a matrix attachment region (MAR)-binding protein and has emerged as a key factor for gene transcription. By regulating many gene expressions through remodeling chromatin architecture, SATB1 is thought to play an essential role in T cell differentiation and activation [4, 24] . Furthermore, this nuclear protein has a cage-like distribution and tethers chromatin loops to a distinct region as a genome organizer [10] . Recently, SATB1 expression has been investigated in some tumors, including human breast cancer [12, 18, 35] . Han et al. reported that high SATB1 expression level was correlated to a high tumor malignancy and poor prognosis in human breast cancer [18] . By reprogramming gene expression, SATB1 has been thought to make tumor cells more aggressive. Snail, which is the zinc finger transcription factor and one of the genes regulated by SATB 1, has been described as a mediator of epithelial-mesenchymal transitions (EMTs) [6, 18] . EMTs are characterized by loss of cell adhesion molecules and gain of mesenchymal markers [33] . In human breast cancer, Snail was reported as an important key mediator of tumor cell invasion and metastasis by induction of EMT [7, 29] . However, the roles of SATB1 and Snail in CMTs have not been clear.
The aim of this study was to assess the utility of biomarkers for cytological examination to predict tumor malignancy and invasiveness by comparison of mRNA levels of ER, PR, HER2, SATB1 and Snail between benign and malignant CMTs and between non-invasive and invasive CMTs, and to establish a new cytological gene examination using FNB samples.
MATERIALS AND METHODS
Patients: Fifty-five dogs studied included 14 Miniature Dachshunds, 6 Shih-Tzus, 4 Beagles, 3 each of Malteses, Papillons, and Shetland Sheepdogs, 2 each of American Cocker Spaniels, Miniature Schnauzers, Welsh Corgi Penbrakes, West Highland White Terriers, and Cavalier King Charles Spaniels, 1 each of Great Pyrenees, Poodle, Chihuahua, Japanese Spitz, and Miniature Bull Terrier, and 7 mixed breeds. These dogs had not had any malignant tumors before excisional biopsy except for the malignant mammary tumors. In 15 dogs, ovariohysterectomy (OHE) had been performed prior to the removal of CMTs. One dog with a mammary tumor was male. The dogs' mean age at the time of tumor removal was 10.0 years (range, 4 to 16 years).
Samples: Fifty-six tissue samples were obtained by excisional surgery from 55 dogs with mammary tumors. The tissue samples under 0.03 grams were obtained from the marginal tumor tissues of the specimens. The mean size of the CMTs was 2.9 cm (range, 0.5 to 11 cm). FNB samples were obtained by inserting 22-G needles into the tumors through the skin in 31 CMTs prior to tissue sample collection. After these sampling, mammary tumors were examined histopathologically by a veterinary pathologist and classified according to the WHO classification [28] . Based on the histopathological examination, the CMTs were categorized into benign or malignant, and non-invasive or invasive. Invasive tumor was defined as tumor with infiltrative growth into the surrounding normal tissues or lymph and blood vessels. All tissue or cytological samples were immersed with RNAlater (Applied Biosystems, Foster City, CA, U.S.A.) overnight at 4°C or 30 min on ice, followed by removal of the RNAlater and storage at -80°C.
RNA isolation and reverse transcription polymerase chain reaction (RT-PCR): Total RNA was isolated from mammary tumors using an RNeasy Mini kit (Qiagen, Hilden, Germany). DNAse digestion was performed using an RNase-Free DNase kit (Qiagen). cDNA was synthesized from 1 yg of tRNA with ReverTra Ace reverse transcriptase (Toyobo, Osaka, Japan) and oligo dT primers (Toyobo) according to the manufacturer's instructions.
Quantitative RT-PCR (qRT-PCR) analysis: cDNA that had been diluted for the amplification of the target genes (ER, PR, HER2, SATB1, and Snail) was used for qRT-PCR analysis. A standard curve for each gene was produced using 100-and 10-fold serial dilutions of the genes as a template (108, 106, 10n, and 103 copies). The reaction was performed using a Quantitect SYBR Green PCR kit (Qiagen) and an iQ5/MyiQ Single-Color (Bio-Rad Laboratories, Hercules, CA, U.S.A.) following the manufacturer's instructions, run as triplicates of each sample. The copy number of each gene expressed in CMTs was calculated from a standard curve and normalized to that of ribosomal protein 19 (RP19). Each primer sequence is shown in Table 1 .
Statistical analysis: The Mann-Whitney U test was used to analyze the differences in the mRNA expression levels of target genes between benign and malignant CMTs, and between non-invasive and invasive CMTs, with P<0.05 considered significant. The genes that had significantly different expressions among these categories were selected for discriminant analysis. Each tumor sample was classified into these categories by discriminant analysis. The relationship between tissue and FNB samples in gene expression was analyzed by Spearman's rank correlation coefficient. Data analyses were carried out with Excel Toukei 2010 (SSRI, Tokyo, Japan).
RESULTS
Histologic study: The 56 tissue samples consisted of 28 benign CMTs (2 simple adenomas, 18 complex adenomas, 8 mixed tumors) and 28 malignant CMTs (12 simple carcinomas, 13 complex carcinomas, 1 adenocarcinoma, 1 carcinosarcoma, 1 osteosarcoma); of the malignant CMTs, 16 showed tumor invasiveness to the surrounding normal tissues or lymph and blood vessels.
Gene expressions and discriminant analysis of tissue samples: The expression level of ER appeared significantly higher in benign (median, 0.01; average, 0.03) CMTs than in malignant (median, 0.002; average, 0.006) CMTs. The difference in ER expression between non-invasive (median,
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OF CANINE MAMMARY TUMORS 721 (Fig. 1C) . The expression levels of SATB1 were similar in benign (median, 0.1; average, 0.15) and malignant (median, 0.1; average, 0.2) CMTs, but expression levels were significantly higher in invasive (median, 0.14; average, 0.33) CMTs than in non-invasive (median, 0.09; average, 0.13) CMTs (Fig. 1D ). In particular, SATBI expression levels were high in samples from patients that had a relapse of CMTs or died within six months after tumor excision (data not shown). Snail was similarly expressed in benign (median, 0.05; average, 0.05) and malignant (median, 0.06; average, 0.16) CMTs, but there was a significant difference in Snail expression between non-invasive (median, 0.04; average, 0.07) and invasive (median, 0.07; average, 0.2) CMTs (Fig. 1E) . To predict the histological malignancy of each tumor based on gene expression, ER and PR, which showed significant differences between benign and malignant CMTs, were used for the discriminant analysis. The total accuracy of classification was 73.2% (Table 2A) . Four genes (ER, PR, SATBI, and Snail) that had significant differences between non-invasive and invasive CMTs were used for the discriminant analysis to predict tumor invasiveness. The total accuracy of classification was 80.0% (Table 2B) . Gene expressions and discriminant analysis of FNB samples: Quantification of gene expressions was performed in 31 FNB samples from the CMTs, including 21 benign and 10 malignant CMTs. Seven FNB samples were from invasive CMTs. HER2 was excluded from the target genes for FNB analysis because of the tissue sample results. Significant differences in ER expressions that were observed in tissue samples were well preserved in FNB samples. High expressions of ER in benign (median, 0.06; average, 0.08) and non-invasive (median, 0.05; average, 0.08) CMTs and low expressions of ER in malignant (median, 0.002; average, 0.008) and invasive (median, 0.002; average, 0.005) CMTs were identified in FNB samples ( Fig. 2A) . PR expression levels of FNB samples were significantly higher in benign (median, 0.07; average, 0.15) CMTs than in malignant (median, 0.004; average, 0.008) CMTs (Fig. 2B) . Moreover, a difference in PR expression was also detected between non-invasive (median, 0.06; average, 0.13) and invasive (median, 0.004; average, 0.007) CMTs. However, a tendency for higher expressions of SATBI and Snail in invasive tissue samples was not detected in FNB samples ( Fig.  2C and 2D ). On discriminant analysis of FNB samples, ER and PR were used for classification, along with both tumor malignancy and invasiveness. Using the two genes, 61.9% of benign and 100% of malignant CMTs, as well as 62.5% of non-invasive and 100% of invasive CMTs, were correctly classified (total accuracy was 74.2 and 71.0%, respectively) ( Benign ( Protein overexpression of HER2 by malignant CMTs has been reported in several studies. However, there was no difference in HER2 expression between benign and malignant or between non-invasive and invasive CMTs. Ahern et al. reported overexpression of HER2 mRNA in 17 of 23 malignant CMTs, but in none of 5 benign CMTs [1] . A recent study reported no differences in the HER2 mRNA levels between adenomas and carcinomas or between presence and absence of lymph node involvement of CMTs [23] . In human breast cancer, reports on the interaction between mRNA expression and HER2 protein or DNA amplification levels did not reach agreement [5, 13] . Since there was no significant difference in HER2 expression among CMT tissue samples in the present study, HER2 was not assessed in FNB samples.
This study investigated the mRNA expressions of SATBI and Snail in CMT tissue, and expressions of both SATBI and Snail were clearly higher in invasive CMTs than in non-invasive CMTs. One sample which expressed remarkably high SATBI or Snail might influence on the statistical analysis. However, the each sample was not excluded from the analysis because of their association with clinical features. The tissue sample expressing very high SATBI was obtained from the invasive CMT with involved lymph node and the skin metastasis were occurred two months after the operation. The other CMT expressing high very Snail was osteosarcoma with vascular invasion, and their aggressive behaviors have been generally known [27] . Further, other samples with high level of SATBI correlated with a poor clinical outcome. Moreover, comparison of the amino acid sequence of canine and human SATB1 showed that two important domains of canine SATB 1 for DNA binding and homodimerization had 100% similarity to human SATB 1 (data not shown). These results suggest that the canine SATB1 may also regulate tumor metastasis genes, such as Snail, to make tumor cells a more aggressive phenotype, as in human breast cancer. However, in the FNB samples, no differences in the expression levels of SATBI and Snail between invasive CMTs and non-invasive CMTs were detected. The cause of this result might be the possibility that small amounts of tumor cells express SATBI and Snail. Recent studies in human based on the expression of EMT markers reported that EMT occurred in a more local region at the invasive area of the tumor [8] . It might be difficult to collect SATBI and Snail-expressing tumor cells in the limited area sampled by FNB.
On discriminant analysis using gene expression levels of ER, PR, SATBI, and Snail, 73.2% of all tissue samples were correctly classified as benign or malignant CMTs, and 80.0% of all tissue samples were correctly classified as noninvasive or invasive CMTs. In FNB samples, expression levels of ER and PR had a high positive correlation to those in tissue samples. ER and PR might be suitable biomarkers for cytological gene examination. In addition, using gene expression levels of ER and PR, the accuracy of 74.2% for tumor classification according to malignancy was as the same as for tissue samples, and that for invasiveness (71.0%) was slightly lower. Aleen et al. reported that the accuracies of cytological examinations of FNB samples of CMTs by two cytologists were 79% and 66% [2] . It is interesting that FNB samples could be correctly classified as benign or malignant CMTs only by ER and PR levels with a similar accuracy to the report by Aleen et al. However, investigation of more gene expressions that can be detected even in FNB samples is needed to improve the accuracy of cytological gene examination. In this study, there were high percentages of false-positive (number of benign samples diagnosed as malignant) results in tissue and FNB samples (46 and 38%, respectively). Considering the report that concentrations of ER and PR in CMTs tended to vary with estrous cycle stage [15] , it might be a difficult to classify benign or malignant CMTs with 100% accuracy only by ER and PR levels. In the future, use of other genes related to malignancy or, currently, referral for cytological examination might improve the accuracy of FNB samples. mRNA quantification of FNB samples by qRT-PCR cost much money and time, so that a simple gene examination kit should be considered.
In conclusion, the present study suggested that ER and PR are reliable biomarkers for the gene examination of FNB samples, and canine SATBI and Snail might have a role in tumor progression, as in humans. Cytological gene examination could become a useful diagnostic tool that can be performed easily without anesthesia and could predict tumor malignancy and invasiveness prior to surgical removal. To establish cytological gene examination of CMTs, more studies of gene expressions, including key biomarkers that are widely involved in the tumor mechanism, are needed. ET AL. 
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